Alerus Financial NA Acquires 96,743 Shares of Kenvue Inc. (NYSE:KVUE)

Alerus Financial NA lifted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 50.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 288,088 shares of the company's stock after acquiring an additional 96,743 shares during the quarter. Alerus Financial NA's holdings in Kenvue were worth $6,151,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Grove Bank & Trust boosted its position in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue during the fourth quarter worth about $29,000. SRS Capital Advisors Inc. lifted its holdings in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares in the last quarter. Fortitude Family Office LLC grew its position in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc increased its stake in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several research analyst reports. Barclays increased their price objective on shares of Kenvue from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Thursday, March 27th. Evercore ISI started coverage on shares of Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and decreased their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Canaccord Genuity Group increased their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Finally, Piper Sandler boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Kenvue presently has a consensus rating of "Hold" and an average price target of $24.00.

Remove Ads

Kenvue Stock Performance

Shares of KVUE stock traded down $0.10 on Tuesday, hitting $23.89. The company's stock had a trading volume of 2,546,213 shares, compared to its average volume of 16,688,766. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock's 50 day moving average is $22.38 and its 200-day moving average is $22.46. The company has a market capitalization of $45.65 billion, a PE ratio of 45.07, a PEG ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date was Wednesday, February 12th. Kenvue's payout ratio is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.